Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 154

1.

V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules.

Falanga A, Marchetti M, Vignoli A, Balducci D, Russo L, Guerini V, Barbui T.

Exp Hematol. 2007 May;35(5):702-11. Erratum in: Exp Hematol. 2007 Sep;35(9):1476.

PMID:
17577920
[PubMed - indexed for MEDLINE]
2.

Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.

Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC, Colomer D, Villamor N, Bellosillo B, Cervantes F.

Am J Hematol. 2009 Feb;84(2):102-8. doi: 10.1002/ajh.21338.

PMID:
19105233
[PubMed - indexed for MEDLINE]
3.

Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.

Patriarca A, Pompetti F, Malizia R, Iuliani O, Di Marzio I, Spadano A, Dragani A.

Blood Transfus. 2010 Jan;8(1):21-7. doi: 10.2450/2009.0004-09.

PMID:
20104275
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.

Toyama K, Karasawa M, Yamane A, Irisawa H, Yokohama A, Saitoh T, Handa H, Matsushima T, Sawamura M, Miyawaki S, Murakami H, Nojima Y, Tsukamoto N.

Br J Haematol. 2007 Oct;139(1):64-9.

PMID:
17854308
[PubMed - indexed for MEDLINE]
5.

Megakaryopoiesis and platelet function in polycythemia vera and essential thrombocythemia patients with JAK2 V617F mutation.

Hattori N, Fukuchi K, Nakashima H, Maeda T, Adachi D, Saito B, Yanagisawa K, Matsuda I, Nakamaki T, Gomi K, Tomoyasu S.

Int J Hematol. 2008 Sep;88(2):181-8. doi: 10.1007/s12185-008-0129-9. Epub 2008 Jul 10.

PMID:
18612778
[PubMed - indexed for MEDLINE]
6.

Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status.

Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC, Villamor N, Colomer D, Cervantes F.

Haematologica. 2006 Feb;91(2):169-75.

PMID:
16461300
[PubMed - indexed for MEDLINE]
Free Article
7.

Circulating endothelial cells in essential thrombocythemia and polycythemia vera: correlation with JAK2-V617F mutational status, angiogenic factors and coagulation activation markers.

Treliński J, Wierzbowska A, Krawczyńska A, Sakowicz A, Pietrucha T, Smolewski P, Robak T, Chojnowski K.

Int J Hematol. 2010 Jun;91(5):792-8. doi: 10.1007/s12185-010-0596-7. Epub 2010 May 15.

PMID:
20473593
[PubMed - indexed for MEDLINE]
8.

The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera.

Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V, Boiret-Dupré N, Skoda RC, Hermouet S.

Blood. 2006 Sep 15;108(6):1865-7. Epub 2006 May 25.

PMID:
16728702
[PubMed - indexed for MEDLINE]
Free Article
9.

Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia.

De Stefano V, Za T, Rossi E, Fiorini A, Ciminello A, Luzzi C, Chiusolo P, Sica S, Leone G.

Haematologica. 2009 May;94(5):733-7. doi: 10.3324/haematol.13869. Epub 2009 Mar 31.

PMID:
19336736
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood.

Stevenson WS, Hoyt R, Bell A, Guipponi M, Juneja S, Grigg AP, Curtis DJ, Scott HS, Szer J, Alexander WS, Tuckfield A, Roberts AW.

Pathology. 2006 Aug;38(4):336-42.

PMID:
16916724
[PubMed - indexed for MEDLINE]
11.

Frequency and clinical features of the JAK2 V617F mutation in pediatric patients with sporadic essential thrombocythemia.

Nakatani T, Imamura T, Ishida H, Wakaizumi K, Yamamoto T, Otabe O, Ishigami T, Adachi S, Morimoto A.

Pediatr Blood Cancer. 2008 Dec;51(6):802-5. doi: 10.1002/pbc.21730.

PMID:
18802948
[PubMed - indexed for MEDLINE]
12.

Plasma levels of angiogenic factors and circulating endothelial cells in essential thrombocythemia: correlation with cytoreductive therapy and JAK2-V617F mutational status.

Treliński J, Wierzbowska A, Krawczyńska A, Sakowicz A, Pietrucha T, Smolewski P, Robak T, Chojnowski K.

Leuk Lymphoma. 2010 Sep;51(9):1727-33. doi: 10.3109/10428194.2010.500435.

PMID:
20615083
[PubMed - indexed for MEDLINE]
13.

The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.

Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC.

Eur J Haematol. 2007 Dec;79(6):508-15. Epub 2007 Oct 23.

PMID:
17961178
[PubMed - indexed for MEDLINE]
14.

The production of JAK2 wild-type platelets is not downregulated in patients with JAK2 V617F mutant-positive essential thrombocythaemia.

Lambert JR, Gale RE, Linch DC.

Br J Haematol. 2009 Apr;145(1):128-30. doi: 10.1111/j.1365-2141.2009.07597.x. Epub 2009 Jan 12.

PMID:
19222478
[PubMed - indexed for MEDLINE]
15.

Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera.

Panova-Noeva M, Marchetti M, Spronk HM, Russo L, Diani E, Finazzi G, Salmoiraghi S, Rambaldi A, Barbui T, Ten Cate H, Falanga A.

Am J Hematol. 2011 Apr;86(4):337-42. doi: 10.1002/ajh.21974. Erratum in: Am J Hematol. 2011 May;86(5):466. Finazzi, Good [corrected to Finazzi, Guido];Rambaldi, Aueesandrd [corrected to Rambaldi, Alessandro];Barbui, Titiano [corrected to Barbui, Tiziano]; Ten Cate, Huao [corrected to Ten Cate, Hugo].

PMID:
21442635
[PubMed - indexed for MEDLINE]
16.

Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia.

Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, Longo G, Ponziani V, Tozzi L, Pieri L, Santini V, Bosi A, Vannucchi AM; Myeloproliferative Disorders Research Consortium (MPD-RC).

Haematologica. 2008 Jan;93(1):41-8. doi: 10.3324/haematol.11653.

PMID:
18166784
[PubMed - indexed for MEDLINE]
Free Article
17.

Src tyrosine kinase preactivation is associated with platelet hypersensitivity in essential thrombocythemia and polycythemia vera.

Randi ML, Brunati AM, Scapin M, Frasson M, Deana R, Magrin E, Fabris F, Donella-Deana A.

Blood. 2010 Jan 21;115(3):667-76. doi: 10.1182/blood-2008-12-196535. Epub 2009 Nov 12.

PMID:
19965650
[PubMed - indexed for MEDLINE]
Free Article
18.

Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis.

Alvarez-Larrán A, Arellano-Rodrigo E, Reverter JC, Domingo A, Villamor N, Colomer D, Cervantes F.

Ann Hematol. 2008 Apr;87(4):269-76. Epub 2007 Sep 27.

PMID:
17899078
[PubMed - indexed for MEDLINE]
19.

Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia.

Dahabreh IJ, Zoi K, Giannouli S, Zoi C, Loukopoulos D, Voulgarelis M.

Leuk Res. 2009 Jan;33(1):67-73. doi: 10.1016/j.leukres.2008.06.006. Epub 2008 Jul 15.

PMID:
18632151
[PubMed - indexed for MEDLINE]
20.

Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.

Hussein K, Brakensiek K, Buesche G, Buhr T, Wiese B, Kreipe H, Bock O.

Ann Hematol. 2007 Apr;86(4):245-53. Epub 2007 Jan 30.

PMID:
17262192
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk